Proteon Therapeutics Inc. (PRTO) announced Tuesday morning that its Phase 3 study of vonapanitase did not meet its primary endpoint of improved primary unassisted patency compared to placebo.
from RTT - Before the Bell http://ift.tt/2hsHilv
via IFTTT
No comments:
Post a Comment